WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of Merkel cell carcinoma (MCC). Meaningful evidence of anticancer activity has been noted among the limited number of patients with MCC who have received IMGN901. These findings were reported at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, MA, and suggest development for metastatic MCC could be a potential registration path for IMGN901.
